Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease-Reference-Cited by-同舟云学术

Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease

Published:2018-02-21 Issue:7 Volume:48 Page:549-555
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Arai Taeang¹,Atsukawa Masanori¹²,Tsubota Akihito³,Ikegami Tadashi⁴,Shimada Noritomo⁵,Kato Keizo⁶,Abe Hiroshi⁶,Okubo Tomomi¹,Itokawa Norio¹,Kondo Chisa²,Mikami Shigeru⁷,Asano Toru⁸,Chuganji Yoshimichi⁸,Matsuzaki Yasushi⁴,Toyoda Hidenori⁹,Kumada Takashi⁹,Iio Etsuko¹⁰,Tanaka Yasuhito¹⁰,Iwakiri Katsuhiko²

Affiliation:

1. Department of Internal Medicine, Division of Gastroenterology; Nippon Medical School Chiba Hokusoh Hospital; Inzai Japan

2. Department of Internal Medicine, Division of Gastroenterology and Hepatology; Nippon Medical School; Tokyo Japan

3. Core Research Facilities for Basic Science; The Jikei University School of Medicine; Tokyo Japan

4. Department of Internal Medicine, Division of Hepatology and Gastroenterology; Tokyo Medical University, Ibaraki Medical Center; Ibaraki Japan

5. Department of Internal Medicine, Division of Gastroenterology and Hepatology; Otakanomori Hospital; Kashiwa Japan

6. Department of Internal Medicine, Division of Gastroenterology and Hepatology; Shinmatsudo Central General Hospital; Matsudo Japan

7. Department of Internal Medicine, Division of Gastroenterology; Kikkoman General Hospital; Noda Japan

8. Department of Internal Medicine, Division of Gastroenterology and Hepatology; Tokyo Metropolitan Bokutoh Hospital; Tokyo Japan

9. Department of Gastroenterology; Ogaki Municipal Hospital; Ogaki Japan

10. Department of Virology and Liver Unit; Nagoya City University, Graduate School of Medical Sciences; Nagoya Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.13058/fullpdf

Reference35 articles.

1. Hepatitis C disease burden and strategies to manage the burden (guest editors Mark Thursz, Gregory Dore and John Ward);Dore;J Viral Hepat,2014

2. Natural history of chronic hepatitis C;Seeff;Hepatology,2002

3. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study;Yamagata;Kidney Int,2007

4. Hepatitis C infection and chronic renal diseases;Perico;Clin J Am Soc Nephrol,2009

5. Epidemiology of hepatitis C virus infection in patients with renal disease;Garcia-Valdecasas;J Am Soc Nephrol,1994

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Misunderstanding of hepatitis C virus (HCV) infection status by non–specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy;Journal of Infection and Chemotherapy;2022-09

2. Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group;Journal of Medical Virology;2021-07-03

3. Effectiveness and safety of ombitasvir/paritaprevir/ritonavir in treatment of chronic hepatitis C Egyptian hemodialysis patients, case-control study;Egyptian Liver Journal;2021-01-27

4. Development of interferon-free, direct-acting antivirals treatment for Japanese patients with chronic hepatitis C infection and chronic kidney disease;Journal of Nippon Medical School;2021

5. Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study;Infectious Diseases and Therapy;2020-09-08